238 related articles for article (PubMed ID: 16735984)
21. Clinical behavior and genetics of nonsyndromic, familial nonmedullary thyroid cancer.
Bauer AJ
Front Horm Res; 2013; 41():141-8. PubMed ID: 23652675
[TBL] [Abstract][Full Text] [Related]
22. Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium.
Lesueur F; Stark M; Tocco T; Ayadi H; Delisle MJ; Goldgar DE; Schlumberger M; Romeo G; Canzian F
J Clin Endocrinol Metab; 1999 Jun; 84(6):2157-62. PubMed ID: 10372725
[TBL] [Abstract][Full Text] [Related]
23. The incidence of familial nonmedullary thyroid cancer in a large case series.
Zivaljevic V; Paunovic I; Diklic A; Krgovic K; Kalezic N; Kazic M; Tatic S; Savic D; Stojanovic D; Perunovic R
Acta Chir Belg; 2008; 108(3):328-32. PubMed ID: 18710108
[TBL] [Abstract][Full Text] [Related]
24. Familial history of non-medullary thyroid cancer is an independent prognostic factor for tumor recurrence in younger patients with conventional papillary thyroid carcinoma.
Lee YM; Yoon JH; Yi O; Sung TY; Chung KW; Kim WB; Hong SJ
J Surg Oncol; 2014 Feb; 109(2):168-73. PubMed ID: 24132694
[TBL] [Abstract][Full Text] [Related]
25. [Familial nonmedullary thyroid cancer].
Sugino K; Mimura T; Ito K; Ito K
Nihon Rinsho; 2000 Jul; 58(7):1519-22. PubMed ID: 10921335
[TBL] [Abstract][Full Text] [Related]
26. Biological behavior and prognosis of familial papillary thyroid carcinoma.
Ito Y; Kakudo K; Hirokawa M; Fukushima M; Yabuta T; Tomoda C; Inoue H; Kihara M; Higashiyama T; Uruno T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Miyauchi A
Surgery; 2009 Jan; 145(1):100-5. PubMed ID: 19081481
[TBL] [Abstract][Full Text] [Related]
27. Familial Aggregation and Heritability of Nonmedullary Thyroid Cancer in an Asian Population: A Nationwide Cohort Study.
Lin HT; Liu FC; Lin SF; Kuo CF; Chen YY; Yu HP
J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32333767
[TBL] [Abstract][Full Text] [Related]
28. Thyroid cancer of follicular cell origin in inherited tumor syndromes.
Nosé V
Adv Anat Pathol; 2010 Nov; 17(6):428-36. PubMed ID: 20966648
[TBL] [Abstract][Full Text] [Related]
29. A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci.
Tsilchorozidou T; Vafiadou E; Yovos JG; Romeo G; McKay J; Lesueur F; Bonora E
Thyroid; 2005 Dec; 15(12):1349-54. PubMed ID: 16405407
[TBL] [Abstract][Full Text] [Related]
30. Familial nonmedullary thyroid cancer: screening, clinical, molecular and genetic findings.
Navas-Carrillo D; Ríos A; Rodríguez JM; Parrilla P; Orenes-Piñero E
Biochim Biophys Acta; 2014 Dec; 1846(2):468-76. PubMed ID: 25218916
[TBL] [Abstract][Full Text] [Related]
31. Familial nonmedullary thyroid neoplasia.
Rubén Harach H
Endocr Pathol; 2001; 12(2):97-112. PubMed ID: 11579685
[TBL] [Abstract][Full Text] [Related]
32. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
33. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
[TBL] [Abstract][Full Text] [Related]
34. Familial non-medullary thyroid carcinoma: an update.
Nosé V
Endocr Pathol; 2008; 19(4):226-40. PubMed ID: 18931957
[TBL] [Abstract][Full Text] [Related]
35. HABP2 Gene Mutations Do Not Cause Familial or Sporadic Non-Medullary Thyroid Cancer in a Highly Inbred Middle Eastern Population.
Alzahrani AS; Murugan AK; Qasem E; Al-Hindi H
Thyroid; 2016 May; 26(5):667-71. PubMed ID: 26906432
[TBL] [Abstract][Full Text] [Related]
36. HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.
Weeks AL; Wilson SG; Ward L; Goldblatt J; Hui J; Walsh JP
BMC Med Genet; 2016 Aug; 17(1):60. PubMed ID: 27530615
[TBL] [Abstract][Full Text] [Related]
37. Familial thyroid carcinoma: a diagnostic algorithm.
Dotto J; Nosé V
Adv Anat Pathol; 2008 Nov; 15(6):332-49. PubMed ID: 18948764
[TBL] [Abstract][Full Text] [Related]
38. HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Zhang T; Xing M
J Natl Cancer Inst; 2016 Jun; 108(6):djv415. PubMed ID: 26832773
[TBL] [Abstract][Full Text] [Related]
39. An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up.
Sippel RS; Caron NR; Clark OH
World J Surg; 2007 May; 31(5):924-33. PubMed ID: 17429563
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and Management of Hereditary Thyroid Cancer.
Bano G; Hodgson S
Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
